Two Investigational Drugs in Patients With Mixed Hyperlipidemia
The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
Drug: MK0653, ezetimibe
Drug: Comparator: fenofibrate monotherapy
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
|Official Title:||Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia|
- Plasma LDL-C vs. fenofibrate for 12 weeks.
- All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.
|Study Start Date:||January 2003|
The duration of treatment is 18 weeks.